Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Actinium Pharmaceuticals, Inc. due to allegations of violations of federal securities laws related to misleading statements and the approval process of the Iomab-B BLA [3][5]. Group 1: Legal Investigation and Claims - The law firm is encouraging investors who suffered losses exceeding $75,000 in Actinium between October 31, 2022, and August 2, 2024, to discuss their legal rights [1]. - A federal securities class action has been filed against Actinium, with a deadline of May 26, 2025, for investors to seek the role of lead plaintiff [3]. - The complaint alleges that Actinium and its executives made false or misleading statements regarding the likelihood of FDA approval for the Iomab-B BLA [5]. Group 2: Stock Performance and Market Reaction - Following the revelation of the need for an additional clinical trial to support the BLA filing, Actinium's stock price dropped significantly, plummeting $3.69, or nearly 60%, to close at $2.48 on August 5, 2024 [6][7]. - The decline in stock price occurred on unusually high trading volume, indicating a strong market reaction to the news [7]. Group 3: Class Action Participation - The lead plaintiff in a class action is defined as the investor with the largest financial interest who is typical of class members and oversees the litigation [8]. - Any member of the putative class can move the court to serve as lead plaintiff or choose to remain an absent class member without affecting their ability to share in any recovery [8]. Group 4: Additional Information and Contact - Faruqi & Faruqi encourages anyone with information regarding Actinium's conduct, including whistleblowers and former employees, to contact the firm [9].

Core Points - A class action lawsuit has been filed against Actinium Pharmaceuticals, Inc. for alleged securities fraud and unlawful business practices [2][4] - Investors who purchased Actinium securities during the Class Period have until May 26, 2025, to apply as Lead Plaintiff [2] - Actinium's stock price experienced a significant decline of nearly 60% following a regulatory update regarding its Biologics License Application for Iomab-B [4] Company Overview - Actinium Pharmaceuticals, Inc. is involved in the development of therapies for patients with cancer, specifically focusing on acute myeloid leukemia [4] - The company faced a setback when the FDA deemed the Phase 3 SIERRA trial inadequate for supporting a BLA filing for Iomab-B [4] Legal Context - Pomerantz LLP, a law firm specializing in corporate and securities class litigation, is leading the class action against Actinium [5] - The firm has a history of recovering multimillion-dollar damages for victims of securities fraud and corporate misconduct [5]

Core Viewpoint - A class action lawsuit has been filed against Actinium Pharmaceuticals, Inc. for alleged misleading statements regarding its Iomab-B Biologics License Application during the Class Period from October 31, 2022, to August 2, 2024 [1][5]. Group 1: Lawsuit Details - The lawsuit claims that Actinium made false and/or misleading statements about the likelihood of FDA approval for its Iomab-B BLA, particularly regarding data from the Sierra Trial [5]. - It is alleged that the additional analyses provided to the FDA were unlikely to meet the necessary guidelines for approval, leading to potential refusal or rejection of the BLA [5]. - The lawsuit asserts that the misleading statements caused investors to suffer damages when the true situation became known [5]. Group 2: Participation Information - Investors who purchased Actinium securities during the Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - To join the class action, interested parties can visit the provided link or contact the law firm directly for more information [3][6]. - A lead plaintiff must file a motion with the Court by May 26, 2025, to represent other class members in the litigation [1][3]. Group 3: Law Firm Credentials - The Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements and recognition in the field [4]. - The firm has recovered hundreds of millions of dollars for investors, with notable achievements in past years, including over $438 million secured in 2019 [4].

For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003. The Allegations: Robbins LLP is Investigating Allegations that Actinium Pharmaceuticals, Inc. (ATNM) Misled Investors Regarding FDA Approval of Iomab-B SAN DIEGO, March 28, 2025 /PRNewswire/ -- Robbins LLP informs stockholders that a class action was filed on behalf of all persons and entities that purchased or otherwise acquired Actinium Pharmaceuticals, Inc. (NYSE: ATNM) securities between October 31 ...

Core Viewpoint - A securities class action lawsuit has been filed against Actinium Pharmaceuticals, Inc. for allegedly making false and misleading statements regarding its business and the approval process for its Iomab-B BLA [1][2]. Group 1: Allegations and Claims - The lawsuit claims that the defendants failed to disclose that data from the Sierra Trial was unlikely to meet FDA guidelines for the Iomab-B BLA approval [2]. - It is alleged that additional analyses provided to the FDA to support the Sierra Trial's data were also unlikely to satisfy the FDA's requirements [2]. - The complaint suggests that the FDA would likely refuse to review the Iomab-B BLA or that the application would not be approved in its current form [2]. - Defendants' positive statements regarding the company's business and prospects are claimed to be materially misleading [2]. Group 2: Market Reaction - The truth about the inadequacy of the Sierra Trial data began to emerge on August 5, 2024, leading to a significant decline in Actinium's stock price, which harmed investors [3]. Group 3: Investor Information - Investors who acquired shares of Actinium are encouraged to contact the law firm before the lead plaintiff motion deadline on May 26, 2025, to discuss their rights [4].

ATLANTA, March 28, 2025 (GLOBE NEWSWIRE) -- A shareholder class action lawsuit has been filed against Actinium Pharmaceuticals, Inc. (“Actinium” or the “Company”) (NYSE: ATNM). The lawsuit alleges that Defendants made materially false and/or misleading statements, and/or failed to disclose material adverse facts, including allegations that: (i) Actinium “repeatedly touted the Sierra Trial’s positive DCR data while downplaying the study’s failure to generate statistically significant or clinically meaningful ...

-  99.8% tumor growth inhibition achieved with a single dose of ATNM-400 in preclinical prostate cancer models -  ATNM-400 accumulated in tumors for up to 144 hours and showed minimal uptake in healthy tissues in prostate cancer xenograft model - Initial ATNM-400 preclinical data to be presented at AACR including results in Pluvicto resistant prostate cancer models NEW YORK, March 27, 2025 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a pioneer in the develo ...

PALM BEACH, Fla., March 27, 2025 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - Industry experts see the global radiotherapy market continuing to grow in the years to come. A recent report from MarketsAndMarkets said that the global radiotherapy market, which was valued at US$6.23 billion in 2022, grew at a robust CAGR of 4.9%, and reached US$7.21 billion in 2024 and is expected to reach an impressive US$9.62 billion by 2030. It said: "During the forecast years, the growth of the market is attributed ...

- ATNM-400 is a novel, non-PSMA targeting, first-in-class Actinium-225 radiotherapy for prostate cancer with initial preclinical results to be presented at the AACR Annual Meeting - Actinium is establishing radiopharmaceutical manufacturing infrastructure in 2025 to support expanding clinical trials and to leverage its proprietary Actinium-225 cyclotron manufacturing technology - Data from several clinical trials expected in 2H:2025 across myeloid malignancies, solid tumors and cell and gene therapy conditi ...

- Company to highlight recent significant progress made with its Actimab-A and Iomab-ACT clinical programs, leading-edge R&D and radiopharmaceutical manufacturing infrastructure - Revitalized clinical programs focused on 3 separate multi-billion-dollar market opportunities in myeloid malignancies, solid tumors and cell & gene therapy conditioning with clinical data expected in 2025 supporting each addressable market - Presentation follows Investor KOL Event and Company Update on March 25th NEW YORK, March 2 ...